Rapport Therapeutics, Inc.
RAPP
Analytical Summary
Rapport Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.
4-Year Financial Trajectory
AnnualHealth Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
24.3%
Good
Good
Year-over-year change in earnings per share
Optimal:
> 10%
|
83.6%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-42.4%
Weak
Weak
Year-over-year change in net income |
-125.1%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
30.2%
Excellent
Excellent
Year-over-year change in free cash flow |
83.1%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Effective Tax Rate (%) (%) | — |
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
-0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| FCF / Net Income (x) |
0.79x
Caution
↓
Caution
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.86x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.83x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-20.4%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-27.2%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
141.2%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-24.4%
Weak
→
Weak
Stable
Operating profit relative to total assets
Optimal:
> 10%
|
-26.4%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-23.3%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-23.0%
Weak
↓
Weak
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-253%)
|
-25.6%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-271%)
|
135.7%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+805%)
|
— |
Secondary lens
Benchmark Lens
Compare RAPP against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare RAPP against peers after checking the statement evidence.
Percentile Rankings
How RAPP compares to all companies
Peer Comparison
RAPP vs similar peers
Compare RAPP with peers
Stack RAPP against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 14 quarters